Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema [3]

British Journal of Ophthalmology

Volumn 89, Issue 1, 2005, Pages 122-

  Jonas, J B ^a,b   Kreissig, I ^a   Degenring, R F ^a   Kamppeter, B A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; CASE REPORT; DIABETES MELLITUS; DIFFUSE DIABETIC MACULAR EDEMA; FOLLOW UP; HUMAN; INJECTION; INTRAOCULAR PRESSURE ABNORMALITY; LETTER; PRIORITY JOURNAL; RETINA MACULA EDEMA; VISUAL ACUITY;

EID: 11144314751     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.050575     Document Type: Letter

References (5)

1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
2. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6.
3. Jonas JB, Degenring R, Kamppeter B, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular edema. Am J Ophthalmol 2004;(in press).
4. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991;98:807-2.
5. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Opthalmol 2004;122:218-22.